Scholar Rock Holding Corp — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Scholar Rock reported Q2 2026 results with net loss of $109.9M (vs. $110.0M YoY), no revenue, and cash of $492.1M (up $124.5M from Dec 2025, including $62.8M from ATM offering). The lead candidate apitegromab for spinal muscular atrophy (SMA) has an FDA BLA with two independent fill-finish facility pathways toward potential approval by Sept 30, 2026 PDUFA date; a Phase 2 FORGE trial in FSHD initiated; and Phase 1 SRK-439 ongoing with topline data expected late 2026.
Why this rating
Approval pathway de-risking and strong cash position ($492M ≈ 19% of market cap) support near-term commercialization optionality for first-in-class myostatin inhibitor in SMA, a transformational milestone if approved.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.